CD274 and lung cancer: Similarly, Santini et al., 2018 [5] in a real-world cohort of 482 patients with advanced non–small cell lung cancer (NSCLC) treated with anti-PD-(L)1 agents, found that among 68 patients (14%) who developed serious irAEs requiring treatment interruption, 56% were successfully retreated, with 48% showing no recurrent toxicity, while 26% experienced recurrence and 26% developed new irAEs, most of which were mild and manageable.